esophageal cancer

Newly Public Lucid Diagnostics Posts $200K in Preliminary Q3 Revenues

The company's revenues were derived from its EsoGuard Esophageal DNA Test for esophageal cancer and related cell-collection device.

BTIG, Canaccord Genuity Initiate Coverage of Lucid Diagnostics With Buy Ratings

BTIG and Canaccord Genuity said Lucid's products have a total addressable market similar to that of Exact Sciences' Cologuard colorectal cancer screening test.

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing.

Castle Biosciences Acquires Cernostics for up to $80M

Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq

Lucid markets an esophageal DNA test and cell collection device for the detection of gastroesophageal reflux disease, and esophageal precancer and cancer.

Jul 13, 2021

Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing

Jun 10, 2021

Lucid Diagnostics Obtains CE Mark for Esophageal Cancer Molecular Test

Feb 18, 2021

Stella Diagnostics, Mayo Clinic Collaborating on Barrett's Esophagus Protein Markers

Oct 12, 2020

Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

Sep 24, 2020

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Sep 8, 2020

Early Copy Number Changes Predict Progression of Barrett's Esophagus to Esophageal Cancer

Aug 6, 2020

PavMed Raises $7M in Private Funding Round

Jul 1, 2020

AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection
Premium

May 11, 2020

Genetic Ancestry Linked to Differences in Molecular Features of Cancers

Apr 8, 2020